Form 8-K Akari Therapeutics Plc For: Mar 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Akari Therapeutcis (AKTX) Enters $1.615M Private Placement
March 11, 2024 5:26 PM EDTOn March 11, 2024, Akari Therapeutcis (NASDAQ: AKTX) entered into a definitive agreement (the Purchase Agreement) with certain existing investors, pursuant to which the Company agreed to sell and issue in a private placement (the Private Placement) approximately $1,615,000 of unregistered American Depository Shares (ADSs), each representing 2,000 of the Companys ordinary shares, at a to be determined purchase price per ADS equal to the lower of: (i) $1.57 (the product of 0.7 and the official closing price of the ADSs on The Nasdaq Stock Market (Nasdaq) on March 4, 2024, the trading day immediately preceding the public announcement of the Companys entry into... More
